Released Nov 10, 2026, before the open
10-Q filed Nov 10, 2026, 41 days after period end · 0001193125-26-454468
On October 8, 2026, the Company entered into a Stapled Contingent Value Rights Agreement (the CVR Agreement), and the Board of Directors (the Board) declared a dividend of one CVR for each share of Atossa common stock outstanding as of October 19, 2026 and issued thereafter.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$5.64M | -$8.69M | -$7.23M | -$6.23M |
| EPS Diluted | -$0.56 | -$1.01 |
Atossa Therapeutics, Inc. · CIK 1488039 · Engraved from SEC EDGAR
| -$0.06 |
| -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
On October 8, 2026, Atossa entered into a Stapled Contingent Value Rights Agreement and its Board declared a dividend of one CVR for each share of common stock outstanding as of October 19, 2026.¶1
CVR holders are entitled in the aggregate to 25% of net proceeds from the sale or monetization of the first qualifying FDA priority review voucher, up to a maximum aggregate payment of $50 million. No PRV has been awarded to the Company.¶2¶3
Total operating expenses were $5.9 million and $24.5 million for the three and nine months ended September 30, 2026, decreases of $3.4 million and $1.2 million from the 2025 periods.¶4